文献速递心律失常

绝经年龄、绝经后激素治疗与新发心房颤动

Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation.
PubMed 文献 · Heart · 2017-10-07

基于妇女健康研究(WHS)30 034名基线无心血管病和房颤的女性,中位随访20.5年发生1350例房颤。多变量分析显示绝经年龄与房颤风险无显著关联,而单用雌激素的绝经后激素治疗与房颤风险独立相关(HR 1.22;95%CI 1.02-1.45)。

要点

  • 绝经年龄与房颤风险无显著关联。
  • 单用雌激素的激素治疗与房颤风险增加相关。
  • 雌孕激素联合治疗与房颤风险无显著关联。

核心结论

  • 绝经年龄与新房颤风险无显著关联。
  • 单用雌激素的绝经后激素治疗与房颤风险增加独立相关,而雌孕激素联合治疗无此关联。

研究设计与样本

  • 妇女健康研究(WHS)前瞻性队列,1992-1995年入组39 876名女性健康专业人员,本次分析纳入30 034名基线无心血管病和房颤且未在绝经前切除子宫及双侧卵巢的女性,采用Cox比例风险模型。

主要发现

  • 中位随访20.5年,发生1350例房颤事件。
  • 与绝经年龄>54岁相比,<45岁HR 0.82(95%CI 0.67-1.02),45-49岁HR 0.90(95%CI 0.74-1.08),50-54岁HR 0.89(95%CI 0.75-1.06),均无显著差异。
  • 单用雌激素的PHT与房颤风险相关(HR 1.22;95%CI 1.02-1.45),雌孕激素联合治疗HR 1.04(95%CI 0.86-1.26)。
  • 该关联未被中间心血管事件衰减。

临床怎么用

  • 对绝经后女性评估房颤风险时,可关注单用雌激素的激素治疗史。
  • 绝经年龄本身不宜作为房颤风险分层的主要依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Limited data exist on the association between menopause and atrial fibrillation (AF). We sought to examine the relationship between menopausal age, postmenopausal hormone therapy (PHT) use and incident AF. METHODS: The Women's Health Study (WHS) enrolled 39 876 female health professionals between 1992 and 1995. We prospectively examined 30 034 women in WHS using Cox proportional-hazard models. Participants were free of cardiovascular disease and AF at baseline and had not undergone hysterectomy without bilateral oophorectomy prior to menopause. Incident AF was confirmed by medical record review. RESULTS: At baseline, median age was 53 years (IQR 49-60), median menopausal age was 50 years (IQR 46-52) and 14 415 (48.0%) had prior PHT use. Over a median follow-up of 20.5 years, 1350 AF events occurred. In multivariable analysis, relative hazards for AF were lower among women with younger age at menopause but did not differ significantly from women with the oldest menopausal age (<45: HR 0.82, 95% CI 0.67 to 1.02; 45-49: HR 0.90, 95% CI 0.74 to 1.08; 50-54: HR 0.89, 95% CI 0.75 to 1.06; >54 years: referent). Use of oestrogen-alone PHT, but not oestrogen and progesterone, was independently associated with AF risk (HR 1.22; 95% CI 1.02 to 1.45 vs HR 1.04; 95% CI 0.86 to 1.26). This relationship was not attenuated by intermediary cardiovascular events. CONCLUSIONS: In this large prospective study, menopausal age was not significantly related to incident AF, while use of oestrogen monotherapy was associated with increased AF risk. Our findings suggest a pathophysiological link between unopposed oestrogen exposure and AF in women. CLINICAL TRIAL REGISTRATION: NCT000000479; Post-results.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Wong JA, Rexrode KM, Sandhu RK, et al. Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. Heart. 2017. PMID: 28988211. doi:10.1136/heartjnl-2016-311002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。